Ivor Royston: Difference between revisions

Latest revision as of 14:19, 21 February 2025

American oncologist and entrepreneur

Ivor Royston is an American oncologist and entrepreneur known for his pioneering work in the field of biotechnology. He is a co-founder of Hybritech, one of the first biotechnology companies, and has been influential in the development of monoclonal antibodies for cancer treatment.

Early life and education[edit]

Ivor Royston was born in 1945. He pursued his undergraduate studies at Johns Hopkins University, where he developed an interest in medicine and biological sciences. Royston went on to earn his M.D. from the University of Rochester in 1970.

Career[edit]

Academic career[edit]

After completing his medical degree, Royston joined the faculty at the University of California, San Diego (UCSD), where he focused on cancer research. His work at UCSD laid the foundation for his later ventures into biotechnology.

Biotechnology ventures[edit]

In 1978, Royston co-founded Hybritech with Howard Birndorf. Hybritech was one of the first companies to commercialize monoclonal antibodies, which are now a cornerstone in the treatment of various cancers. The success of Hybritech paved the way for the growth of the biotechnology industry in San Diego.

Royston has also been involved in the founding of several other biotechnology companies, including Idec Pharmaceuticals, which later merged with Biogen to form Biogen Idec.

Current work[edit]

Royston continues to be active in the biotechnology field, serving on the boards of various companies and organizations. He is also involved in venture capital, helping to fund and guide new biotechnology startups.

Awards and recognition[edit]

Ivor Royston has received numerous awards for his contributions to medicine and biotechnology. His work has been recognized by various professional organizations, and he is considered a pioneer in the field of biotechnology.

Related pages[edit]

@@ Line 1: / Line 1: @@
-{{Infobox scientist
+{{short description|American oncologist and entrepreneur}}
-| name = Ivor Royston
+{{Use American English|date=October 2023}}
-| image =
+{{Use mdy dates|date=October 2023}}
-| image_size =
-| alt =
-| caption =
-| birth_date = [[March 22]], [[1945]]
-| birth_place = [[Boston, Massachusetts]], [[United States]]
-| nationality = [[American]]
-| fields = [[Oncology]], [[Immunology]]
-| work_institutions = [[University of California, San Diego]], [[Hybritech]], [[Forward Ventures]]
-| alma_mater = [[Johns Hopkins University]], [[Stanford University School of Medicine]]
-| known_for = Co-founding [[Hybritech]], pioneering work in [[monoclonal antibodies]]
-| awards =
-}}
-'''Ivor Royston''' (born March 22, 1945) is an American [[oncologist]] and [[entrepreneur]] known for his pioneering work in the development of [[monoclonal antibodies]] and his role in founding [[biotechnology]] companies. He is a prominent figure in the field of [[cancer research]] and has significantly contributed to the advancement of [[biotechnology]] in [[medicine]].
+[[File:Ivor_Royston_headshot.jpg|thumb|right|Ivor Royston]]
-== Early Life and Education ==
+'''Ivor Royston''' is an American [[oncologist]] and [[entrepreneur]] known for his pioneering work in the field of [[biotechnology]]. He is a co-founder of [[Hybritech]], one of the first biotechnology companies, and has been influential in the development of [[monoclonal antibodies]] for cancer treatment.
-Ivor Royston was born in [[Boston, Massachusetts]]. He pursued his undergraduate studies at [[Johns Hopkins University]], where he earned a Bachelor of Arts degree in 1967. He then attended [[Stanford University School of Medicine]], receiving his M.D. in 1972. During his time at Stanford, Royston developed an interest in [[immunology]] and [[oncology]], which would shape his future career.
-== Career ==
+==Early life and education==
+Ivor Royston was born in 1945. He pursued his undergraduate studies at [[Johns Hopkins University]], where he developed an interest in [[medicine]] and [[biological sciences]]. Royston went on to earn his [[Doctor of Medicine|M.D.]] from the [[University of Rochester]] in 1970.
-=== Academic Career ===
+==Career==
-After completing his medical degree, Royston joined the faculty at the [[University of California, San Diego]] (UCSD) in 1977. At UCSD, he focused on research in [[cancer immunology]] and the development of [[monoclonal antibodies]] for cancer treatment. His work laid the foundation for the use of monoclonal antibodies in [[therapeutics]].
-=== Biotechnology Ventures ===
+===Academic career===
-In 1978, Royston co-founded [[Hybritech]], one of the first biotechnology companies to focus on the development of monoclonal antibody technology. Hybritech's success in developing diagnostic and therapeutic products demonstrated the potential of biotechnology in medicine. The company was later acquired by [[Eli Lilly and Company]] in 1986.
+After completing his medical degree, Royston joined the faculty at the [[University of California, San Diego]] (UCSD), where he focused on [[cancer research]]. His work at UCSD laid the foundation for his later ventures into biotechnology.
-Following the success of Hybritech, Royston continued to be involved in the biotechnology industry. He co-founded [[Forward Ventures]], a venture capital firm that invests in early-stage life science companies. Through Forward Ventures, Royston has supported numerous startups in the biotechnology sector.
+===Biotechnology ventures===
+In 1978, Royston co-founded [[Hybritech]] with [[Howard Birndorf]]. Hybritech was one of the first companies to commercialize [[monoclonal antibodies]], which are now a cornerstone in the treatment of various cancers. The success of Hybritech paved the way for the growth of the biotechnology industry in [[San Diego]].
-== Contributions to Medicine ==
+Royston has also been involved in the founding of several other biotechnology companies, including [[Idec Pharmaceuticals]], which later merged with [[Biogen]] to form [[Biogen Idec]].
-Royston's work in developing monoclonal antibodies has had a profound impact on the treatment of various diseases, particularly [[cancer]]. Monoclonal antibodies are now a standard component of many cancer therapies, providing targeted treatment options that improve patient outcomes.
-== Awards and Recognition ==
+===Current work===
-Ivor Royston has received numerous awards for his contributions to science and medicine. His work has been recognized by various professional organizations, and he continues to be an influential figure in the field of biotechnology.
+Royston continues to be active in the biotechnology field, serving on the boards of various companies and organizations. He is also involved in venture capital, helping to fund and guide new biotechnology startups.
-== Personal Life ==
+==Awards and recognition==
-Royston is married and has children. He remains active in the scientific community and continues to advocate for the advancement of biotechnology in medicine.
+Ivor Royston has received numerous awards for his contributions to medicine and biotechnology. His work has been recognized by various professional organizations, and he is considered a pioneer in the field of [[biotechnology]].
-== Also see ==
+==Related pages==
-* [[Monoclonal antibody therapy]]
+* [[Monoclonal antibody]]
 * [[Biotechnology]]
-* [[Cancer immunotherapy]]
+* [[Cancer treatment]]
 * [[Hybritech]]
-* [[University of California, San Diego]]
-{{Authority control}}
 [[Category:American oncologists]]
-[[Category:American immunologists]]
+[[Category:American medical researchers]]
 [[Category:Biotechnology]]
+[[Category:Living people]]
 [[Category:1945 births]]
-[[Category:Living people]]
-<gallery>
-File:Ivor_Royston_headshot.jpg|Ivor Royston
-File:Ivor_Royston_lab_1978.jpg|Ivor Royston in the lab, 1978
-File:Hybritech_progeny_chart.jpg|Hybritech progeny chart
-</gallery>